Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice

BACKGROUND: Current anti-cancer therapeutic antibodies that are used in the clinic are predominantly humanized or fully human immunoglobulin G1 (IgG1). These antibodies bind with high affinity to the target antigen and are efficient in activating the immune system via IgG Fc receptors and/or complem...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:PLoS One
Egile Nagusiak: Braster, Rens, Grewal, Simran, Visser, Remco, Einarsdottir, Helga K., van Egmond, Marjolein, Vidarsson, Gestur, Bögels, Marijn
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2017
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5438146/
https://ncbi.nlm.nih.gov/pubmed/28542406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0177736
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak